智通财经网·2025-08-26 12:59Core Insights - Fosun Pharma (02196) reported a mid-year performance for 2025, with total revenue of approximately 19.514 billion yuan, a year-on-year decrease of 4.63% [1] - The net profit attributable to shareholders was about 1.702 billion yuan, reflecting a year-on-year increase of 38.96%, with basic earnings per share at 0.64 yuan [1] - Revenue from innovative pharmaceuticals showed robust growth, exceeding 4.3 billion yuan, which is a 14.26% increase compared to the same period last year [1] Financial Performance - The increase in profit is primarily attributed to the gains from the sale of remaining equity in United Family Healthcare and other non-core assets [1] - The net cash flow generated from operating activities was 2.134 billion yuan, marking an 11.90% year-on-year growth [1] Strategic Initiatives - The company is actively optimizing its asset structure by exiting and integrating non-strategic and non-core assets, with total signed disposal projects exceeding 2 billion yuan since the beginning of 2025 [1] - Fosun Pharma is enhancing its innovative research and development system to improve efficiency, employing diverse collaboration models such as independent research, cooperative development, licensing, fund incubation, and industrial investment [1] - In the first half of 2025, the total R&D investment amounted to 2.584 billion yuan, with R&D expenses at 1.717 billion yuan [1]